Orthostatic intolerance
Drug research and approvals for orthostatic intolerance: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 65 studies of orthostatic intolerance are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 65
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Spanish Registry of CardioneuroablationNCT07942207 · Not reported · Fundación de investigación HM · starts Jun 1, 2018
- Comparison of Focal Cryoablation vs. Radiofrequency Cardioneuroablation for BradyarrhythmiasNCT07671898 · Not applicable · Tomsk National Research Medical Center of the Russian Academy of Sciences · starts Sep 1, 2024
- Effects of Breathing Retraining Exercises in Pregnant Females With Postural Orthostatic Tachycardia Syndrome.NCT07579026 · Not applicable · Riphah International University · starts Aug 31, 2025
- Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)NCT07502599 · Not reported · Boston Scientific Corporation · starts Aug 6, 2026
- Autonomic Regulation of Blood Pressure and Heart Rate During Orthostasis and Exercise in Healthy and Hypertensive…NCT07482462 · Not reported · University Medical Centre Ljubljana · starts Oct 15, 2025
- Assesment of the Clinical Benefit of Provocation on Tilt-table in SYNCope Patients, TiltSYNC-trialNCT07459478 · Not applicable · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · starts Oct 30, 2025
- NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes DiseaseNCT07398508 · Phase 1 / Phase 2 · Stephen G. Kaler · starts Aug 10, 2026
- POLish Registry of CArdioneuroablation and CArdioneuromodulationNCT07196397 · Not reported · SABAMED Medical Center Ltd. · starts Nov 21, 2024
- The STAND-UP StudyNCT07195903 · Not applicable · St. Francis Hospital, New York · starts Jan 23, 2025
Phase 3 2
- IvabradinePotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
- Albumin humanBilirubin sequestering agent
Phase 2 5
- MetoprololBeta-1 adrenergic receptor antagonist
- ProgesteroneProgesterone receptor agonist
- GanirelixGonadotropin-releasing hormone receptor antagonist
- Efgartigimod alfaIgG receptor FcRn large subunit p51 antagonist
- Sucrose
Phase 1 or earlier 12 of 15
- AtenololBeta-1 adrenergic receptor antagonist
- ClonidineAdrenergic receptor alpha-2 agonist
- MetoclopramideDopamine D2 receptor antagonist
- PropranololBeta-1 adrenergic receptor antagonist
- NitroprussideSoluble guanylate cyclase activator
- AtomoxetineNorepinephrine transporter inhibitor
- DroxidopaAdrenergic receptor agonist
- AtropineMuscarinic acetylcholine receptor M3 antagonist
- EdrophoniumAcetylcholinesterase inhibitor
- IsoproterenolAdrenergic receptor beta agonist
- Methyldopa (racemic)
- PhenylephrineAdrenergic receptor alpha-1 agonist
How its trials ended
45 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 5 whose ending is known, 0% met their primary endpoint, 20% missed it and 80% stopped early.
- Completed, result not reported1636%
- Ongoing1533%
- Status unknown920%
- Stopped: enrollment or feasibility24%
- Missed its primary endpoint12%
- Stopped: funding12%
- Stopped: other or unclear12%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA